Inflammatory biomarkers predicting long-term remission and active disease in juvenile idiopathic arthritis: a population-based study of the Nordic JIA cohort

2024-9-1

Comparison of established and preliminarily proposed ASAS MRI working group cut-offs for inflammatory MRI lesions in the sacroiliac joints in radiographic and non-radiographic axial spondyloarthritis

2024-9-1

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024-9-1

Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease

2024-9-1

Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

2024-9-1

Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study

2024-9-1

miRNAs as potential biomarkers for subclinical atherosclerosis in Sjögren’s disease

2024-8-1

Diagnostic accuracy of serum biomarkers to identify giant cell arteritis in patients with polymyalgia rheumatica

2024-8-1

More severe parotid gland histopathology in paediatric-onset than in adult-onset Sjögren’s disease

2024-8-1

‘Gout was like the boss’. A qualitative study exploring the impact of gout on employment

2024-8-1

Sensitivity of classification criteria from time of diagnosis in an incident systemic lupus erythematosus cohort: a population-based study from Norway

2024-8-1

Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre

2024-8-1

Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis

2024-8-1

Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk

2024-8-1

Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series

2024-8-1

Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis

2024-8-1

Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren’s disease

2024-8-1

Efficacy of BAFF inhibition and B-cell depletion in non-obese diabetic mice as a spontaneous model for Sjögren’s disease

2024-8-1

Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS)

2024-8-1

Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial

2024-8-1

Arrhythmia in patients with systemic sclerosis: incidence, risk factors and impact on mortality in a Swedish register-based study

2024-8-1

Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis

2024-8-1

Bridging the gap: facilitating the use of rheumatology research results in clinical practice with hybrid implementation effectiveness studies

2024-7-1

Course of paediatric ANCA-associated glomerulonephritis: advocating for an age-inclusive approach

2024-7-1

What role do socioeconomic and clinical factors play in disease activity states in rheumatoid arthritis? Data from a large UK early inflammatory arthritis audit

2024-7-1

Tapering csDMARD or TNFi first: is the risk of flares different for ACPA-positive or ACPA-negative rheumatoid arthritis?

2024-7-1

Diagnosis challenges in inception cohorts in axial spondyloarthritis: the case of the French national DESIR cohort

2024-7-1

Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND

2024-7-1

Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

2024-7-1

Sensitivity to change of structural outcomes in axial spondyloarthritis after 10 years of follow up. Data from the DESIR cohort

2024-7-1

Early clinical response associates with long-term outcomes with ixekizumab in radiographic axial spondyloarthritis

2024-7-1

Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?

2024-7-1

Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children

2024-7-1

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study

2024-7-1

Acetylated bacterial proteins as potent antigens inducing an anti-modified protein antibody response

2024-7-1

Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

2024-7-1

No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry

2024-7-1

Is there a role for novel supplements in the management of fatigue in rheumatic diseases?

2024-7-1

International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe

2024-6-1

Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis

2024-6-1

Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus

2024-6-1

Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis

2024-6-1

Inflammation in the posterior elements, in particular the facet joint and facet joint ankylosis over 2-year follow-up in radiographic axial spondyloarthritis

2024-6-1

Synthesis of guidance available for assessing methodological quality and grading of evidence from qualitative research to inform clinical recommendations: a systematic literature review

2024-6-1

Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study

2024-6-1

Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse

2024-6-1

Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients

2024-6-1

Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies

2024-6-1

Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study

2024-6-1

Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database

2024-6-1